3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cyclophosphamide
14
Rituximab
13
Magnetic Resonance Spectroscopy
8
obinutuzumab
7
fludarabine phosphate
7
fludarabine
6
Specimen Handling
6
Prednisone
6
Etoposide
6
Biopsy
6
tocilizumab
5
polatuzumab vedotin
5
ibrutinib
5
X-Rays
5
Whole-Body Irradiation
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
5
Melphalan
5
Lenalidomide
5
Doxorubicin
5
venetoclax
4
Mycophenolic Acid
4
Cytarabine
4
Cyclosporine
4
Busulfan
4
glofitamab
3
acalabrutinib
3
Vincristine
3
Tacrolimus
3
Nivolumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
Hizentra
×
30 days
×
Clear all
NCT07582432
2026-05-12
SIGMA
Grifols Biologicals, LLC
Phase 3
Recruiting
49 enrolled